Breakthrough in Premature Ejaculation Treatment: Combination Therapy Phase 3 Trial Results
A Phase 3 trial of 795 men has found that combining clomipramine and sildenafil dramatically outperforms either drug alone for premature ejaculation, with more than 55% of the combination group reporting their condition was "much improved" or "very much improved".
A New Standard of Care in Sight
Premature ejaculation (PE) remains the most common sexual dysfunction in men under 40, yet it is often undertreated. While selective serotonin reuptake inhibitors (SSRIs) and PDE5 inhibitors like sildenafil have been used off-label for years, many patients find the results inconsistent. Results from a comprehensive Phase 3 clinical trial presented at the end of 2025 have unveiled a potential new standard of care: a combination therapy that significantly outperforms current single-drug treatments.
The multicenter study, led by Professor Du Geon Moon of Korea University, followed 795 men diagnosed with lifelong or acquired premature ejaculation. Participants were randomised into three groups: 15 mg of clomipramine alone, 50 mg of sildenafil alone, or a fixed-dose combination of both. The primary measure of success was the Intravaginal Ejaculatory Latency Time (IELT), measured by participants and their partners using a stopwatch over a 12-week period.
The Power of Synergy
The findings revealed a dramatic additive effect when the two drugs were combined. Men in the combination group saw their average IELT increase to 279 seconds (roughly 4.6 minutes) — a significant improvement over the clomipramine-only group (192 seconds) and the sildenafil-only group (168 seconds).
Beyond the stopwatch, over 55% of men in the combination group reported their condition was "much improved" or "very much improved" — a significantly higher satisfaction rate than those on either drug alone. The researchers noted that while sildenafil is primarily used for erections, its inclusion likely helped reduce the performance anxiety and sympathetic nervous system overactivity that often triggers early ejaculation.
Safety and Tolerability
One major concern with combining medications is the potential for compounded side effects. However, the trial found the combination was remarkably well-tolerated. The most common adverse events were mild nausea (7.5%), headache (9%), and facial flushing (8%). No participants in the combination group reported serious cardiovascular events.
Professor Moon emphasised that this on-demand approach — taking the medication only when needed — is a significant advantage over daily SSRI regimens, which can lead to long-term side effects like weight gain or emotional blunting. "This combination therapy provides a faster, more effective, and safer alternative for men who have not found success with existing treatments," he stated. The success of this Phase 3 trial paves the way for a new class of dual-action PE medications to reach the global market.
More from Pendex
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personal health concerns.